NASDAQ:ALLR Allarity Therapeutics Q3 2025 Earnings Report $1.04 -0.01 (-0.95%) Closing price 10/1/2026 04:00 PM EasternExtended Trading$1.06 +0.02 (+1.92%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Allarity Therapeutics EPS ResultsActual EPS-$0.19Consensus EPS -$0.23Beat/MissBeat by +$0.04One Year Ago EPSN/AAllarity Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AAllarity Therapeutics Announcement DetailsQuarterQ3 2025Date11/14/2025TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AUpcoming EarningsAllarity Therapeutics' next earnings date is estimated for Friday, November 13, 2026, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Allarity Therapeutics Earnings HeadlinesReviewing Allarity Therapeutics (NASDAQ:ALLR) and Autolus Therapeutics (NASDAQ:AUTL)October 1 at 6:15 AM | americanbankingnews.comAllarity Provides Update on Key Recent Advances Solidifying Drug Response Predictor® to Drive Stenoparib’s Clinical DevelopmentSeptember 30 at 1:58 PM | finance.yahoo.comThe end of AI data centers coming?Marc Chaikin's Power Gauge system flagged Micron before it soared 970 percent, Celestica before a 6,600 percent run, and Nvidia before it climbed more than 50,000 percent. Now Chaikin says a new AI data center technology using 99 percent less electricity, water, and space could accelerate scientific breakthroughs 360-fold, and one company behind it just flashed bullish in his system. See the full research and the ticker Chaikin is watching before this presentation goes offline. | Chaikin Analytics (Ad)Allarity Provides Update on Key Recent Advances Solidifying Drug Response Predictor® to Drive Stenoparib's Clinical DevelopmentSeptember 30 at 9:00 AM | globenewswire.comAllarity Therapeutics Expands Laboratory Capabilities to Include Proteomics and Cell Line ResearchSeptember 28, 2026 | globenewswire.comAscendiant Capital Markets Forecasts ALLR Q3 EarningsSeptember 27, 2026 | americanbankingnews.comSee More Allarity Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Allarity Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Allarity Therapeutics and other key companies, straight to your email. Email Address About Allarity TherapeuticsAllarity Therapeutics (NASDAQ:ALLR) is a clinical-stage biotechnology company focused on developing personalized cancer treatments. The company uses its Drug Response Predictor (DRP) technology to analyze tumor biology and identify patients who may be more likely to respond to specific therapies. Allarity’s development programs have included dovitinib, an oral multikinase inhibitor investigated for use in advanced cancers, as well as other oncology candidates and drug-specific DRP companion diagnostics. The company’s approach is intended to support patient selection and improve the efficiency of clinical development by matching treatments with patients whose tumors are predicted to be sensitive to them. The business has roots in Denmark and the United States. It was previously known as Oncology Venture A/S before adopting the Allarity Therapeutics name, reflecting its emphasis on precision oncology and its proprietary response-prediction platform. Its programs remain focused on the development of targeted therapies and diagnostic tools for cancer care.View Allarity Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Micron’s Earnings Reveal Why the AI Memory Boom May Last LongerAnthropic's IPO Could Put Amazon's and Alphabet's Paper Profits to the TestBoeing’s Fighter Victory Opens the Door to Decades of Defense RevenueCleared for Takeoff: AAR Corp. Expands Its Aerospace Aftermarket ReachJabil’s Double-Beat and Raise Is a Signal That This Rally Will ContinueMicrosoft's AI Spending Didn't Change—Wall Street's View of It DidL3Harris’ $6 Billion THAAD Win Comes at a Crucial Moment for the Stock Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
